Introduction
Chronic Fatigue Syndrome (CFS) is a common condition (up to 2% of the USA/UK population is affected) characterized by profound and persistent fatigue. CFS affects people of all ages, and can great reduce a sufferer's ability to function on a daily basis, work or attend school. Despite its impact on the population, the cause of CFS remains unknown. 1 One of the problems that limits study of the pathogenesis of CFS and the development of therapies is the lack of objective diagnostic/disease quantification tools. In the absence of such tools, it is even unclear whether CFS patients are a homogenous disease group, or whether different pathological processes contribute to a common end result of fatigue.
Several strands of research point to abnormalities of the vascular system and its regulation by the autonomic nervous system (particularly in response to standing) as common in CFS, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] although the literature in this area is complex and contradictory, with a number of studies failing to identify such links. 17, 18 The apparent association between clinical features of autonomic dysfunction and CFS mirrors emerging findings in a number of other, unrelated disease settings, including multiple sclerosis, Parkinson's disease and primary biliary cirrhosis (PBC), where similar associations between dysfunction of the autonomic nervous system and fatigue have been noted. [19] [20] [21] [22] [23] One interpretation of these observations in CFS and other fatigueassociated conditions is that abnormalities in autonomic nervous system regulation could provide an overarching pathogenic mechanism (albeit one induced by different pathogenetic processes in the individual diseases) that leads to the result of fatigue. If correct, this model would have profound implications for the treatment of fatigue in these conditions.
A major limitation of the existing studies of autonomic dysfunction in CFS (and a potential explanation for why findings of autonomic dysfunction have yet to translate into new therapies) is the lack of sensitivity of the assessment modalities. A further limitation has been the tendency in the field to carry out small-scale observational studies with limited control groups. We set out to comprehensively assess the prevalence, degree and associations of symptoms of autonomic dysfunction in a large and well characterized group of CFS patients matched to normal controls, and patients with PBC (a patient group with a well characterized association between autonomic dysfunction and fatigue) using the comprehensive and highly sensitive Composite Autonomic Symptom Scale (COMPASS). The COMPASS has been validated against a laboratory-based haemodynamic autonomic function test, 24 and has been used effectively to identify autonomic dysfunction in a wide variety of conditions, including Parkinson's disease and diabetes. [24] [25] [26] [27] [28] 
Methods

Study design
In Phase 1, symptoms of fatigue and autonomic dysfunction were assessed and compared in CFS patients and fully age-and sex-matched population controls, and COMPASS data from the normal population were used to define a diagnostic criterion for the presence of significant autonomic dysfunction. In Phase 2, we attempted to replicate and confirm the symptom association data in a mixed CFS population control population, to test the validity of the diagnostic criterion, and to study its applicability to PBC patients.
Subjects
Patients with CFS were recruited via the Northern CFS network, and through the local patient support group, ME North East. All fulfilled the Fukuda clinical diagnostic criteria for CFS, and all major potential secondary causes for fatigue had been excluded, as per the standard CFS service protocol. 29 Normal controls were recruited from the local population through advertisements inviting people to participate in research into the autonomic nervous system (no selection was made on the basis of presence or absence of fatigue). Patients with PBC were recruited through the local patient support group. All PBC subjects had early-stage liver disease and all had normal liver synthetic function at the time of the study. Subjects were excluded from all study groups if they had potential secondary causes for fatigue, and/or autonomic dysfunction such as diabetes mellitus or hypothyroidism, or were taking medications that could lead to fatigue or symptoms suggestive of autonomic dysfunction. All subjects returned questionnaires anonymously, and local research ethics committee approval ruled that return of the questionnaire implied consent, as it allowed the subject to 'opt in'.
Assessing severity of fatigue
All participants completed the Fatigue Impact scale (FIS). This tool has been validated for selfcompletion in primary biliary cirrhosis 30 and has also been used in both normal populations and in those with CFS.
Assessing symptoms of autonomic dysfunction
The population frequency and severity of symptoms of autonomic dysfunction were assessed using the COMPASS, 24 which consists of 73 questions that assess symptoms, grouped into domains relating to individual aspects of the autonomic nervous system. Each domain is scored on the basis of presence, severity, distribution, frequency and progression of symptoms. The eight domains relate to: The measure also includes a male erectile dysfunction domain, which was not included in this study. The individual domain scores are then weighted according to clinical relevance, as described in the original derivation and validation of the questionnaire. 24 Individual scores are then summed to provide an indicator of total overall symptom burden (total COMPASS score). Two further scales (Understatement and Psychosomatic scales) are incorporated into the assessment tool, and are scored independently from the COMPASS score itself. These scales are aimed at detecting over-or under-reporting of symptoms between individuals; an example of an understatement question is, 'Have you ever in your adult life had difficulty keeping your mind on your job?'. These validity scales allow assessment of whether the subject has actively engaged in completion of the questionnaire. In all scales, higher scores indicate a greater symptom load, with the highest total possible score (excluding the erectile dysfunction domain) being 170.
Validation of COMPASS against objective measurement of autonomic function in CFS
To test the validity of COMPASS for the study of symptoms of autonomic dysfunction in CFS, it was compared with objective measures of autonomic function for use in CFS in 15 representative CFS patients. All assessments were performed at the same time of day, in a quiet room with constant ambient temperature, in a dedicated Cardiovascular Investigation Unit. All subjects were asked to refrain from caffeine or smoking for the 12 h prior to the study, and had a light breakfast prior to assessment. The integrity of the autonomic nervous system was measured over 10 min using continuous digital photo-plethysmography (Taskforce, CNSystems) to obtain resting baroreflex sensitivity and heart rate variability (HRV), and using spectral analysis 31 to derive total power (power spectral density), low frequency heart rate variability (LF, predominantly sympathetic), high frequency heart rate variability (HF, predominantly parasympathetic) and very low frequency heart rate variability (VLF). The LF/HF ratio was considered an indicator of the balance between the sympathetic and parasympathetic nervous systems. Autonomic parameters were correlated against total COMPASS scores for each individual.
Statistical analysis
All COMPASS domain and total scores were normally distributed, and comparisons were therefore made between groups using parametric tests. The Understatement and Psychosomatic scales were found to be skewed, and therefore comparisons were made using non-parametric analyses. Correction for multiple testing using multi-domain measures used the Bonferroni correction.
Results
Phase 1 (derivation phase)
In phase 1 of the study, COMPASS and FIS scores were assessed in 40 CFS/ME and 40 fully age-and sex-matched population controls (9 males and 31 females in each group, mean AE SD ages 45.5 AE 16.8 and 45.5 AE 17.8, respectively). As expected, the CFS patients were significantly more fatigued than the normal controls (mean AE SD FIS 94 AE 32 vs. 14 AE 13, p < 0.0001). Total COMPASS score was significantly higher in CFS patients than in controls (Figure 1a) , and was correlated with FIS ( Figure 1b) . The upper limit for a normal COMPASS score was defined as the mean þ2SD for the normal population cohort scores (32.5). By this definition, 30/40 (75%) of CFS patients had COMPASS scores suggesting autonomic dysfunction.
When the individual domains of the COMPASS were assessed, significant differences were seen between the CFS patient and the population control groups (after correction for multiple testing) for the Orthostatic Tolerance, Vasomotor, Secretomotor, Gastrointestinal (total and Autonomic Diarrhoea sub-domain), Pupil Response and Sleep disorder domains of the COMPASS, but not for the Bladder and Syncopal domains and the Gastrointestinal Constipation subdomain (Table 1 ). These findings suggest that CFS is associated with a substantial, and broadly-based (but not universal), burden of symptoms relating to autonomic dysfunction. In keeping with previous literature describing abnormal haemodynamic responses to standing, one of the dominating differences between CFS patients and population controls is with regard to the Orthostatic Tolerance (OT) domain, where CFS patients had mean scores almost four-fold higher than controls (Figure 2a) . Moreover, the OT domain was the only COMPASS domain for which scores showed a significant correlation with fatigue severity (Figure 2a) . The COMPASS includes sub-scales (potential range 0-10) that assess understatement of symptom severity and psychosomatic symptomatology. Interestingly, the CFS patients were actually marginally more likely to understate their symptoms (as assessed in this way) than population controls, though not significantly so (CFS 2.1 AE 2.9 vs. controls 1.8 AE 2.4, p ¼ NS). Psychosomatic symptoms were greater in CFS patients than in controls, but scores were below 1 in both groups, indicating low overall impact from psychosomatic symptoms (CFS 0.8 AE 1.2 vs. controls 0.1 AE 0.4, p < 0.05). There was no significant relationship between increasing fatigue and the Understatement scale or the Psychosomatic scale in the CFS group, suggesting that increasing fatigue was not associated with increased over-or under-recognition of autonomic symptoms. To determine whether autonomic symptom burden was related to length of disease, CFS patients were also invited to self-report the number of years over which they had experienced fatigue. There was no significant relationship between length of history of fatigue and either total COMPASS score or any individual domain score (data not shown).
Phase 2 (validation phase)
In the second phase of the study we set out to; (i) confirm our phase 1 findings of a strong association between fatigue and autonomic dysfunction in CFS; (ii) to validate our diagnostic criterion for the presence of fatigue-associated autonomic dysfunction (COMPASS 432.5) in 30 CFS patients (23 females, mean age 53.5 AE 8.1 years) and 37 controls (29 females, mean age 50.2 AE 14.5 years); and (iii) to explore the utility of this diagnostic criterion in a second condition in which autonomic dysfunction has been linked to the expression of fatigue (primary biliary cirrhosis, 60 patients, all female, mean age 58.7 AE 12.3). Our previous observation of significantly higher COMPASS scores in CFS patients than in normal controls was confirmed in the validation group (Figure 3) . COMPASS scores were also significantly higher in PBC patients than in normal controls, confirming previous observations suggesting a strong association between PBC and autonomic dysfunction. COMPASS scores were in fact significantly higher in CFS patients than in patients with PBC, a disease in which there is strong evidence of a causal link between fatigue and autonomic dysfunction.
Next we used the phase 2 groups to validate the diagnostic criterion for significant autonomic dysfunction of COMPASS432.5 identified in phase 1 of the study. For the mixed group of CFS patients and population controls (n ¼ 67), COMPASS 432.5 had a positive predictive value for the presence of CFS of 0.96 (95%CI 0.86-0.99) and a negative predictive value of 0.84 (0.70-0.93) ( 2 ¼ 40.5, p < 0.0001). Finally, given autonomic dysfunction was present in our PBC, as well as our CFS patients, we addressed the broader question of the value of COMPASS432.5 as a diagnostic criterion for the presence of significant fatigue-associated disease. For the purposes of this study, significant fatigue was defined as FIS 440.0 (based on mean FIS score þ2SD for the normal control population in phase 1 of the study), which was applied to the whole phase 2 population of 127 CFS patients, PBC patients, and normal controls. In this mixed group, COMPASS 432.5 had a positive predictive value for the presence of significant fatigue of 0.89 (0.78-0.96) and a negative predictive value of 0.74 (0.62-0.84) ( 2 ¼ 50.1, p < 0.0001).
Relationship between total COMPASS scores and heart rate variability Strong significant correlations were seen between heart rate variability, measured during 10 min rest, and both the orthostatic tolerance domain (data not shown) and the total COMPASS score. There was an increasingly impaired sympathetic function (LF HRV) with higher COMPASS score (Figure 4a ), while parasympathetic function (HF HRV) was higher with higher scores (Figure 4b) . Taken together there, was a change in the sympatho-vagal balance with higher COMPASS scores (Figure 4c ).
Discussion
Our data show a clear and significant association between CFS (identified using the established Fukuda criteria) 30 and the symptoms of autonomic dysfunction (identified using the COMPASS score). Interestingly, autonomic symptoms were not universal in those diagnosed with CFS, which may go some way towards explaining the conflicting literature in this area. Also, although broadly-based, the association did not cover the full range of autonomic symptoms. A particularly strong association was seen with symptoms of orthostatic intolerance, suggesting that abnormality of dynamic blood pressure regulation is particularly associated with fatigue severity in CFS/ME. In the first phase of the study, we defined a diagnostic criterion for significant abnormality of the COMPASS score (COMPASS 432.5). In the second phase of the study we confirmed our observations on the association between CFS and COMPASS scores, and validated this diagnostic criterion using a mixed CFS and normal population group, with a positive predicted value of 96% and a negative predicted value of 84%.
Three conclusions can be drawn from this component of the study. First, autonomic dysfunction (as identified by the COMPASS score) is a frequent feature of patients with CFS (75% of this CFS patient group). Second, the finding of a significantly elevated COMPASS was highly specific to patients with CFS, in a mixed group of CFS patient and normal controls. Third, COMPASS 432.5 appears to be a robust, reproducible and objective diagnostic tool for identifying a significant CFS sub-population in whom autonomic dysfunction is a prominent disease feature.
The contrast between the findings of this study and earlier studies that failed to identify a link between autonomic dysfunction and CFS may well reflect the robust diagnostic criteria for CFS in this study, and the favourable psychometric properties of the COMPASS, although the routes we used for patient recruitment, including through local patient support groups, may have contributed to identifying a particularly symptomatic CFS patient group. The strong relationship seen in the validation element of the study between COMPASS scores and heart rate variability (an objective measure of autonomic function) strongly suggests that the COMPASS is indeed identifying autonomic dysfunction.
Although the majority of CFS patients in both our study cohorts had significantly elevated COMPASS scores, a minority of patients did not. Severity of fatigue was similar in patients with high and with low COMPASS scores, suggesting that we may have identified subgroups of CFS with potentially different aetiological mechanisms. Interestingly, this division into dysautonomia-associated and non-dysautonomia-associated fatigue has recently been observed in primary biliary cirrhosis, where 60% of patients have significant fatigue. 19, 20, 23 We therefore applied our diagnostic criterion to a group of mixed PBC patients. In this group of 60 patients, of whom 37 had significant fatigue, our COMPASS score diagnostic criterion had a positive predictive value for presence of fatigue of 83% and a negative predictive value of 60%. Of the 37 fatigued patients, 25 (67%) met our COMPASS diagnostic criterion for significant autonomic dysfunction.
These findings appear to confirm that dysautonomia is a feature of some, but not all, fatigued PBC patients, and also show that our COMPASS diagnostic criterion is about equally good at identifying fatigue-associated dysautonomia in PBC and in CFS patients. Our findings thus have implications for the broader context of autonomic dysfunction and disease. Further studies are needed to elucidate the multiple mechanisms responsible for the expression of fatigue in complex disease settings, but our findings support the hypothesis that autonomic dysfunction is a common pathway to the development of fatigue that can be triggered by a number of seemingly disparate disease processes. Further research is also needed to explore whether autonomic dysfunction arises as a primary defect, or secondary to abnormalities such as volume depletion. Previous research approaches have tended to look at single diseases in isolation, which may have contributed to important 'cross-cutting' aetiological mechanisms for fatigue being missed. Our data support the concept of a common process (dysautonomia-associated fatigue, DAF) that may be responsible for some fatigue development in several disease settings, and which may be amenable to common approaches to treatment ( Figure 5 ). This model needs to be tested and confirmed in CFS and PBC, and extended to other fatigue-associated disease settings.
Initial enthusiasm for therapeutic approaches should be tempered by the recognition that dysautonomia-directed approaches to therapy have, to date, proved disappointing in clinical practice. However, the limited apparent response to therapy may reflect that only some CFS patients have autonomic dysfunction-associated fatigue (and thus would be expected to respond to such therapies). Our observation that autonomic dysfunction is a feature in only a proportion (albeit a significant one) of CFS patients, and our identification of a diagnostic criterion to identify such patients, should allow better-targeted therapeutic trials.
This study aimed to examine the strength and nature of the association between the symptoms of autonomic dysfunction and fatigue in CFS, and to identify diagnostic criteria for significant autonomic dysfunction. It did not aim to reveal the nature of the association. One key question is whether the development of autonomic dysfunction in CFS patients is causally related to the development of fatigue. It may be, for example, that autonomic dysfunction occurs as a consequence of physical or behavioural changes in fatigued patients, and such deconditioning has previously been postulated as an explanation for the presence of autonomic dysfunction in CFS patients. However, the existence of a clear group of significantly fatigued CFS patients who do not exhibit autonomic dysfunction, suggests, at the very least, that deconditioning is not a universal phenomenon. Further, there was no association between the degree of autonomic dysfunction as assessed by COMPASS and the length of time that patients had experienced fatigue as part of their CFS. If autonomic dysfunction resulted from deconditioning caused by impaired activity, more prolonged experience of fatigue should be associated with increased autonomic dysfunction.
Studies in other conditions in which fatigue is associated with autonomic dysfunction, such as PBC, have demonstrated associations between physical parameters of blood pressure regulation (including on dynamic testing in the context of tilt testing) and severity of fatigue. 19, 21, 23 Ongoing studies in PBC are addressing the extent to which these blood pressure dysregulation phenomena affect peripheral muscle function through oxygen delivery abnormalities. Such studies are badly needed in CFS, and identification of a diagnostic criterion for fatigue-associated dysautonomia in CFS will assist in the design of such studies by enabling the identification of suitable subjects. These studies will be of real importance, not only for our understanding of the pathogenesis of fatigue in a significant proportion of CFS patients, but also, potentially, in the design of treatments for these patients.
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Non-DAF Fatigue Fatigued Non-Fatigued Figure 5 . Model for the role played by dysautonomiaassociated fatigue (DAF) in the clinical expression of CFS and PBC. DAF represents a 'cross-cutting' phenomenon that can contribute to the expression of fatigue in seemingly disparate conditions. In CFS (in which all patients are by definition fatigued), DAF is present in the majority of patients. The non-DAF minority of CFS presumably have fatigue generated by other pathological processes. In PBC (in which only a proportion of patients are fatigued), DAF is present in a sizeable minority of patients. In contrast to CFS, the pathological processes responsible for the non-DAF fatigue component in PBC have begun to be identified, and include excessive daytime somnolence. The implication of this model is that dysautonomia-directed approaches to therapy should be restricted in CFS (and, indeed, PBC patients) to the DAF subgroup of patients. Failure to restrict the application of these approaches in this way may help explain the apparent lack of efficacy of these approaches in clinical trials to date.
